Finding the right patient services model isn’t a simple task. Traditionally, rare disease manufacturers have been served by multi-channel models made up of disparate service providers, each claiming expertise in their specific capabilities. The result…a rise in costs and a fall in outcomes as shown by average patient adherence data ranging between 58 to 65 percent. But this doesn’t have to be the case, and many companies are shifting their focus to more integrated models that drive better patient outcomes and financial results.
Access a new infographic from Dohmen Life Science Services here. Learn how an integrated and exclusive model with unique wrap-around services helps reduce unnecessary costs and helps manufacturers maintain control of your economics, inventory, brand, program and patients.
............................................................................................................................................................................................................................................................................